Dra. Olga María Rivero Martín

Investigador Emergente
Grupo de Investigación en Psiquiatría y Enfermedades Neurodegenerativas

Dr. Olga Rivero’s research career focuses on improving our understanding of how risk genes for neuropsychiatric and neurodevelopmental disorders impact on brain function and ultimately on behavior. She is biologist and developed her undergraduate and PhD research career at the Department of Genetics, University of Valencia, with focus on the genetics of schizophrenia.

As a postdoctoral researcher, she moved to the Division of Molecular Psychiatry, University of Würzburg, to study the neurobiology of attention deficit / hyperactivity disorder. In Würzburg, she experienced a strong shift to new methodologies and approaches which have enriched her research career to a great extent, ranging from cellular imaging and functional studies, to phenotyping of genetically modified mice at the molecular, cellular and systems levels, always with a translational perspective.

Back to the Spanish academia, Dr. Rivero obtained in 2021 a Miguel Servet Contract to work as Emergent Researcher at the INCLIVA Research Group on Psychiatry and Neurodegenerative Disorders. In this new stage, she will focus in the generation of neuronal cell lines from healthy subjects and first episode of psychosis (FEP) patients, in order to identify biomarkers of psychosis and poor medication response. This project will be supported by Carlos III Health Institute.

In addition, during her whole research career, Dr. Rivero has participated in the publication of 31 manuscripts, (25 of them in the first Quartile, 10 of them as main author) as well as in the supervision of 3 PhD, 1 MD, 7 bachelor and 8 master theses.

Dra. Olga María Rivero Martín



Al-Soufi, L., Martorell, L., Moltó, M. D., González-Peñas, J., García-Portilla, M. P., Arrojo, M., Rivero, O., Gutiérrez-Zotes, A., Nácher, J., Muntané, G., Paz, E., Páramo, M., Bobes, J., Arango, C., Sanjuan, J., Vilella, E., & Costas, J. (2022). A polygenic approach to the association between smoking and schizophrenia. Addiction biology, 27(1), e13104. https://doi.org/10.1111/adb.13104

Martínez-Pinteño, A., Mezquida, G., Bioque, M., López-Ilundain, J. M., Andreu-Bernabeu, Á., Zorrilla, I., Mané, A., Rodríguez-Jiménez, R., Corripio, I., Sarró, S., Ibáñez, Á., Usall, J., Rivero, O., Gassó, P., Leza, J. C., Cuesta, M. J., Parellada, M., González-Pinto, A., Berrocoso, E., Mas, S., … 2EPs Group (2022). The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 57, 105–117. https://doi.org/10.1016/j.euroneuro.2022.02.003

Wang, Y., Cao, Y., Hays, C. L., Laboute, T., Ray, T. A., Guerrero-Given, D., Ahuja, A. S., Patil, D., Rivero, O., Kamasawa, N., Kay, J. N., Thoreson, W. B., & Martemyanov, K. A. (2021). Adhesion GPCR Latrophilin 3 regulates synaptic function of cone photoreceptors in a trans-synaptic manner. Proceedings of the National Academy of Sciences of the United States of America, 118(45), e2106694118. https://doi.org/10.1073/pnas.2106694118

Rivero, O., Alhama-Riba, J., Ku, H. P., Fischer, M., Ortega, G., Álmos, P., Diouf, D., van den Hove, D., & Lesch, K. P. (2021). Haploinsufficiency of the Attention-Deficit/Hyperactivity Disorder Risk Gene St3gal3 in Mice Causes Alterations in Cognition and Expression of Genes Involved in Myelination and Sialylation. Frontiers in genetics, 12, 688488. https://doi.org/10.3389/fgene.2021.688488

Vitale, M. R., Zöller, J., Jansch, C., Janz, A., Edenhofer, F., Klopocki, E., van den Hove, D., Vanmierlo, T., Rivero, O., Nadif Kasri, N., Ziegler, G. C., & Lesch, K. P. (2021). Generation of induced pluripotent stem cell (iPSC) lines carrying a heterozygous (UKWMPi002-A-1) and null mutant knockout (UKWMPi002-A-2) of Cadherin 13 associated with neurodevelopmental disorders using CRISPR/Cas9. Stem cell research, 51, 102169. https://doi.org/10.1016/j.scr.2021.102169

Rovira, P., Demontis, D., Sánchez-Mora, C., Zayats, T., Klein, M., Mota, N. R., Weber, H., Garcia-Martínez, I., Pagerols, M., Vilar-Ribó, L., Arribas, L., Richarte, V., Corrales, M., Fadeuilhe, C., Bosch, R., Martin, G. E., Almos, P., Doyle, A. E., Grevet, E. H., Grimm, O., Halmøy A, Hoogman M, Hutz M, Jacob CP, Kittel-Schneider S, Knappskog PM, Lundervold AJ, Rivero O, … Ribasés, M. (2020). Shared genetic background between children and adults with attention deficit/hyperactivity disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 45(10), 1617–1626. https://doi.org/10.1038/s41386-020-0664-5

Mortimer, N., Sánchez-Mora, C., Rovira, P., Vilar-Ribó, L., Richarte, V., Corrales, M., Fadeuilhe, C., Rivero, O., Lesch, K. P., Casas, M., Ramos-Quiroga, J. A., Artigas, M. S., & Ribasés, M. (2020). Transcriptome profiling in adult attention-deficit hyperactivity disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 41, 160–166. https://doi.org/10.1016/j.euroneuro.2020.11.005

Forero, A., Ku, H. P., Malpartida, A. B., Wäldchen, S., Alhama-Riba, J., Kulka, C., Aboagye, B., Norton, W., Young, A., Ding, Y. Q., Blum, R., Sauer, M., Rivero, O., & Lesch, K. P. (2020). Serotonin (5-HT) neuron-specific inactivation of Cadherin-13 impacts 5-HT system formation and cognitive function. Neuropharmacology, 168, 108018. https://doi.org/10.1016/j.neuropharm.2020.108018

Corominas, J., Klein, M., Zayats, T., Rivero, O., Ziegler, G. C., Pauper, M., Neveling, K., Poelmans, G., Jansch, C., Svirin, E., Geissler, J., Weber, H., Reif, A., Arias Vasquez, A., Galesloot, T. E., Kiemeney, L., Buitelaar, J. K., Ramos-Quiroga, J. A., Cormand, B., Ribasés, M., … Lesch, K. P. (2020). Identification of ADHD risk genes in extended pedigrees by combining linkage analysis and whole-exome sequencing. Molecular psychiatry, 25(9), 2047–2057. https://doi.org/10.1038/s41380-018-0210-6


Referencia: PI22/01985
Título: Proyecto Miguel Servet. Development and characterization of new preclinical models for personalized medicine in psychoses.
Entidad Financiadora: Instituto de Salud Carlos III
Investigador principal: Olga Rivero
Duración: 2022 – 2026
Presupuesto: 308.600 €

Referencia: PI22/01985
Título: Desarrollo y caracterización de nuevos modelos preclínicos celulares de medicina personalizada en Psicosis
Entidad Financiadora: Instituto de Salud Carlos III
Investigador principal: Olga Rivero
Duración: 2023 – 2024
Presupuesto: 117.370 €